FCCC LOGO Faculty Publications
Haas NB , Manola J , Hudes G , Citrin DL , Kies MS , Davis TE
Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer
Am J Clin Oncol. 2000 Dec;23(6) :589-92
Back to previous list
Abstract
Twenty-nine patients with progressive hormone-refractory metastatic adenocarcinoma of the prostate were treated with daily estramustine phosphate at 10 mg/kg, and I.V. doxorubicin 50 mg/m2 every 3 weeks. Twenty-six patients were evaluable. Four of seven patients with nonosseous measurable disease had partial responses lasting 3 to 10 months. Eleven of 19 patients with osseous metastases had stable disease or improvement on bone scan, 6 of these for 7 months or longer. Median time to progression was 20 weeks, and the median survival was 43 weeks.
Notes
21071567 0277-3732 Clinical Trial Clinical Trial, Phase II Journal Article